Evidence map›Paper›PMID 41731198›Full record

ArticleEuropean journal of clinical pharmacology2026

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy - an analysis of Swiss pharmacovigilance data.

Céline K Stäuble, Valeriu Toma, Thomas Stammschulte, Samuel S Allemann, Henriette E Meyer Zu Schwabedissen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Céline K StäubleBiopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, 4056, Switzerland. celine.staeuble@unibas.ch.ORCID http://orcid.org/0000-0002-2437-4803
Valeriu TomaPharmacovigilance, Safety of Medicines Division, Swissmedic, Bern, 3012, Switzerland.
Thomas StammschultePharmacovigilance, Safety of Medicines Division, Swissmedic, Bern, 3012, Switzerland.
Samuel S AllemannPharmaceutical Care, Department of Pharmaceutical Sciences, University of Basel, Basel, 4056, Switzerland.
Henriette E Meyer Zu SchwabedissenBiopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, 4056, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStatin associated musculoskeletal symptoms (SAMS) are common adverse drug reactions reported by 20% of statin users and are assumed to be dose dependent. The organic anion transporting polypeptide 1B1 (OATP1B1), a hepatocellular uptake transporter, modulates the systemic exposure of statins. The concurrent use of OATP1B1 inhibitors can increase systemic statin exposure and thus increase the risk of SAMS.

methodsIndividual case safety reports (ICSRs) of suspected adverse drug reactions (ADRs), like SAMS, are an important data source to monitor the safety of marketed drugs. We used the Swissmedic database to analyse the prevalence of potential OATP1B1 involving interactions in cases of suspected SAMS.

resultsIn 54% of the ICSRs analysed, at least one substance with OATP1B1 inhibiting properties was used together with a statin. Antidiabetic and cardiovascular drugs were the most commonly reported substances with OATP1B1 inhibiting properties.

conclusionOur findings could indicate clinically relevant OATP1B1 involving interactions in SAMS, which should be further investigated.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1Muscular DiseasesAdverse Drug Reaction Reporting SystemsDrug InteractionsHumansHypoglycemic AgentsPharmacovigilancePrevalenceSwitzerlandHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsLiver-Specific Organic Anion Transporter 1SLCO1B1 protein, humanAdverse drug reactionAtherosclerotic cardiovascular diseaseDrug-drug interactionDrug safetyDrug transportHepatocellular uptake

Identifiers

PMID41731198
PMCPMC12929307

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.